Gilead Sciences Inc will invest US$5.1 billion to increase its stake in Galapagos NV and partner with the Belgian-Dutch biotech firm to develop and commercialize its treatments for a ten-year period, the companies said on Sunday.
Gilead deepens Galapagos ties with US$5.1 billion deal
